ALLO · Allogene Therapeutics, Inc.
$2.05
+0.07 (+3.54%)
At close · Aug 14
Market Cap
$708.26M
Shares
345.49M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$190.89M
+25.9%
FY2025
Operating Margin
-1241813.64%
-896827.3pp
FY2024
Diluted EPS
-$0.87
+34.1%
FY2025
Operating Cash Flow
-$149.25M
+25.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $22K | $95K | $156K | $114.09M | $0 | $0 | — | |
| $3M | $2.6M | $100K | — | — | — | — | — | — | |
| $122.52M | $150.15M | $192.3M | $242.91M | $256.39M | $220.18M | $192.99M | $144.54M | $151.86M | |
| $62.44M | $56.78M | $65.21M | $71.67M | $79.31M | $74.11M | $65.26M | $57.47M | $40.98M | |
| — | — | — | — | $0 | $0 | $151K | $603K | $452K | |
| — | $12.36M | $13.64M | $14.2M | $14.3M | $10.5M | $7.4M | $4.6M | $1M | |
| — | $4.75M | — | — | — | — | — | — | — | |
| $184.96M | $209.32M | $273.22M | $327.83M | $335.69M | $294.28M | $258.24M | $202.01M | $192.84M | |
| -$180.32M | -$209.32M | -$273.2M | -$327.74M | -$335.54M | -$180.19M | -$258.24M | -$202.01M | -$192.84M | |
| — | — | -1241813.64% | -344986.32% | -215087.18% | -157.94% | — | — | — | |
| — | -$196.96M | -$259.56M | -$313.54M | -$321.24M | -$169.69M | -$250.84M | -$197.41M | -$191.84M | |
| $1.3M | $1.08M | $181K | $0 | — | — | $0 | $0 | $3.36M | |
| $14.82M | $18.43M | $16.05M | $472K | -$4.88M | -$1.86M | -$58.14M | $17.08M | -$18.78M | |
| — | $0 | -$1.69M | -$10.67M | — | — | — | — | — | |
| — | -$190.89M | -$257.15M | -$327.27M | — | -$257.01M | -$250.22M | -$184.93M | -$211.62M | |
| — | $0 | $443K | $0 | $0 | $0 | $0 | -$331K | -$117K | |
| -$165.49M | -$190.89M | -$257.59M | -$327.27M | -$340.41M | -$182.05M | -$316.38M | -$184.59M | -$211.51M | |
| — | — | -1170863.64% | -344489.47% | -218214.1% | -159.57% | — | — | — | |
| -$165.97M | -$190.53M | -$256.72M | -$318.29M | -$347.77M | -$184.89M | -$317.26M | -$183.76M | -$211.2M | |
| USD/shares | — | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | — |
| USD/shares | — | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | — |
| shares | — | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M |
| shares | — | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M | 120.37M | 101.06M | 28.95M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.98×
EV/EBIT
—
Peer median 23.46×
P/E (TTM)
—
Peer median 12.66×
Peer medians compare against the 318 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $0 | $22,000 | $95,000 |
Key facts
CIK
1737287
CUSIP
019770106
13F (30d)
203 filings
200 filers
Visit website
Investor relations